SIM1803-1A / Simcere, WuXi AppTec - LARVOL DELTA

An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations. (clinicaltrials.gov) - P1 | N=24 | Terminated | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | N=243 ➔ 24 | Recruiting ➔ Terminated; Business strategy

Enrollment change • Trial termination • Oncology • Solid Tumor

An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations. (clinicaltrials.gov) - P1; N=243; Recruiting; Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology • Solid Tumor

An Open, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations. (clinicaltrials.gov) - P1; N=243; Not yet recruiting; Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Clinical • New P1 trial • Oncology • Solid Tumor

Simcere kicks off China Phase I for innovative multi-kinase inhibitor (GBI Health) - "GBI SOURCE database indicates that China-based Simcere Pharmaceutical Group (2096.HK) has initiated a Phase I clinical study (CTR20202292) for SIM1803-1A, a next-generation kinase inhibitor targeting TRK A/B/C and ROS1. The drug is set to be developed as a treatment for locally advanced/metastatic solid tumors with mutations of NTRK, ROS1, and ALK fusion genes."

New P1 trial • Oncology • Solid Tumor